<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03498183</url>
  </required_header>
  <id_info>
    <org_study_id>RC18_0052</org_study_id>
    <nct_id>NCT03498183</nct_id>
  </id_info>
  <brief_title>Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (≥15 mm) Classified Bethesda III or IV on Cytology</brief_title>
  <acronym>MIBI-THYR</acronym>
  <official_title>Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (Sup or Egal to 15 mm) Classified Bethesda III or IV on Cytology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to show that the addition of ultrasonography to the dual
      tracer scintigraphy MIBI-Tc99m/Iodine-123 will increase (at least +5%) the negative
      predictive value compared to the dual tracer scintigraphy alone in detection of malignancy in
      thyroid nodules ≥15 mm classified as Bethesda III-IV on cytology.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All the patients will have the scintigraphie with MIBI-Tc99m/Iodine-123</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Addition of ultrasonography to the dual tracer scintigraphy MIBI-Tc99m/Iodine-123 will increase the negative predictive value compared to the dual tracer scintigraphy alone.</measure>
    <time_frame>Month 36</time_frame>
    <description>Scintigraphy MIBI-Tc99m/Iodine-123</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the correlation between dual scintigraphy (MIBI/Iodine-123) and cervical ultrasonography (with Ti-RADS score).</measure>
    <time_frame>Month 36</time_frame>
    <description>Spearman's correlation coefficient between measures obtained using dual scintigraphy (MIBI/Iodine-123) and cervical ultrasonography (with Ti-RADS score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of diagnostics properties of MIBI/Iodine-123 scintigraphy for detection of thyroid malignancy.</measure>
    <time_frame>Month 36</time_frame>
    <description>Estimation of the sensitivity of MIBI/Iodine-123 scintigraphy for detection of thyroid malignancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of diagnostics properties of MIBI/Iodine-123 scintigraphy for detection of thyroid malignancy.</measure>
    <time_frame>Month 36</time_frame>
    <description>Estimation of the specificity value of MIBI/Iodine-123 scintigraphy for detection of thyroid malignancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of diagnostics properties of MIBI/Iodine-123 scintigraphy for detection of thyroid malignancy.</measure>
    <time_frame>Month 36</time_frame>
    <description>Estimation of the positive predictive value of MIBI/Iodine-123 scintigraphy for detection of thyroid malignancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of diagnostics properties of Ti-RADS scoring.</measure>
    <time_frame>Month 36</time_frame>
    <description>Quality of life measured using the scores of the SF36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of diagnostics properties of Ti-RADS scoring.</measure>
    <time_frame>Month 36</time_frame>
    <description>Quality of life measured using an evaluation of the voice measured using a specific autoquestionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of diagnostics properties of Ti-RADS scoring.</measure>
    <time_frame>Month 36</time_frame>
    <description>Quality of life measured using the scores of EQ-5D questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of diagnostics properties of the best combination of the scintigraphic values (intensity of MIBI and Iodine uptakes) to improve the diagnostic properties.</measure>
    <time_frame>Month 36</time_frame>
    <description>Research of the best thresholds on scintigraphic values (intensity of MIBI and Iodine uptakes) to improve the diagnostic properties (details of scores are given in &quot;5.3.3. Role of Nuclear Medicine Physician&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the MIBI washout</measure>
    <time_frame>Month 36</time_frame>
    <description>MIBI washout estimated using the percentage reduction value of mean MIBI uptake between early (10 min) and late (&gt;60 min) scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness analysis (economic efficiency) at 10 years comparing the systematic surgery strategy to the non-systematic strategy guided by imagery.</measure>
    <time_frame>Month 36</time_frame>
    <description>Incremental cost-effectiveness ratio (cost per Quality-Adjusted Life-Year, QALY) of the comparison between the systematic surgery strategy to the non-systematic surgery strategy guided by imagery over a 10 years' time horizon.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness analysis (economic efficiency) at 10 years comparing the systematic surgery strategy to the non-systematic strategy guided by imagery.</measure>
    <time_frame>year 10</time_frame>
    <description>Incremental cost-effectiveness ratio (cost per Quality-Adjusted Life-Year, QALY) of the comparison between the systematic surgery strategy to the non-systematic surgery strategy guided by imagery over a 10 years' time horizon.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">321</enrollment>
  <condition>Malignancy of Thyroid Nodules</condition>
  <arm_group>
    <arm_group_label>ARM experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All the patients will have MIBI-Tc99m/Iodine-123 . Following the injections they will have a scintigraphy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MIBI-Tc99m/Iodine-123</intervention_name>
    <description>Following the injection of MIBI-Tc99m/Iodine-123 , the patients will have a scintigraphy.</description>
    <arm_group_label>ARM experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient over 18 years with a thyroid nodule ≥15 mm (maximal diameter measured on
             US) with a Bethesda class III or IV (FNA less than 6 months before the surgery).

          -  Given signed, written informed consent

          -  Affiliation to a social security system.

          -  Neither-pregnant nor breast-feeding women.

          -  Use of efficient contraception for patient with pregnancy potential (if needed).

        Exclusion Criteria:

          -  Underage and adults under guardianship.

          -  Pregnant, without efficient contraception (if needed) or breast feeding women.

          -  Administration of iodinated contrast in the previous 3 weeks.

          -  Contraindication to scintigraphy or to Iodine123/ MIBI 99Tc administration

          -  Treatment containing iodine (i.e. : Amiodarone)

          -  Hypo or hyperthyroidism treated or not.

          -  Nodules inferior 15 mm.

          -  Refusal to sign the consent.

          -  Refusal of surgical treatment or contraindication for surgery or anesthesia

          -  Morbid obesity (BMI Superior 40 kg/m2).

          -  Hyperparathyroidism.

          -  History of cervicotomy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric Mirallié, MD</last_name>
    <email>eric/mirallie@chu-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nelly Renaud-Moreau</last_name>
    <email>Nelly.RENAUDMOREAU@chu-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier et Universitaire (chu)</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>HAMY</last_name>
      <email>Anhamy@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>chaffanjon</last_name>
      <email>Pchaffanjon@chu-grenoble.fr'</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pattou</last_name>
      <email>'Fpattou@univ-lille2.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathonnet</last_name>
      <email>Mathonnet@unilim.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lifante</last_name>
      <email>'Jean-christophe.lifante@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Mirallié</last_name>
      <email>eric.mirallie@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assistance publique des Hôpitaux de Paris</name>
      <address>
        <city>Paris</city>
        <zip>75 000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabrice Menegaux</last_name>
      <email>Fabrice.menegaux@psl.aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2018</study_first_submitted>
  <study_first_submitted_qc>April 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2018</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Nodule</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iodine</mesh_term>
    <mesh_term>Cadexomer iodine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

